(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) rose 9.58% to $2.35 at 11:41 EST on Wednesday, following the last session’s downward trend. NASDAQ is sliding 1.25% to $10,483.75, after three consecutive sessions in a row of gains. This seems, as yet, an all-around down trend trading session today.

Inovio Pharmaceuticals’s last close was $2.14, 72.46% under its 52-week high of $7.77.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Earnings per Share

Inovio Pharmaceuticals’ trailing 12 months profit per share was $-1.073.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -70.1%.

Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $2.35 at 11:41 EST, way below its 52-week high of $7.77 and way higher than its 52-week low of $1.38.

Revenue growth

The year-on-year revenue growth fell by 46.4%. We now have 1.6M in the 12 trailing months.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 20.5% and 3.4%, respectively.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 3555325 which is 37.84% below its average volume of 5720250.

More news about Inovio Pharmaceuticals (INO).

LEAVE A REPLY

Please enter your comment!
Please enter your name here